The importance of inflammation burden ("inflammatory/pathogenic burden") for the cardiac aging.

Trial Profile

The importance of inflammation burden ("inflammatory/pathogenic burden") for the cardiac aging.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2015

At a glance

  • Drugs Fluvastatin (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders
  • Focus Pharmacodynamics
  • Acronyms Anti-CardAgeing
  • Most Recent Events

    • 11 Oct 2014 Trial status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 18 Sep 2012 Planned End Date changed to 19 Apr 2012.
    • 07 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top